Observations from Conferences
Payers Leverage Off Label Bevacizumab to Control Opht Costs
Keeping It Fair in Rare -- What every Pharma can Learn from Orphan/Ultra-Orphan Sales Incentives Plan Design
$200,000 the new max? Payers start to redefine “Proven and Medically Necessary”
Claims Data Analytics. Now Available for Pipeline Brands.
Alignments from scratch in hours, not weeks, not months. Data included.
You Won President's Club. Again. Great! Now What?
Ultra Orphan IC Design
Observations from Tableau Conference 2016
Observations from 2017 JPM
© 2017 Qral Group LLC